Phase II clinical trial - VADS
U31287-A-U203 / Patritumab
VADS
Essai clinique fermé
Public cible
Adulte
RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 2 STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH CETUXIMAB PLUS PLATINUM-BASED THERAPY IN FIRST LINE SETTING IN SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK.
Description de l'essai
This is a randomized double blinded trial evaluating the efficacy of the combination of carboplatine with cetuximab and patritumab (antibody targeting HER3) in patients with recurrent head and neck cancer whose tumor harbour an overexpression of heregulin (HER3 ligand). Heregulin expression is assessed in the US from archival tissue.
Liens utiles
CHRISTOPHE LE TOURNEAU
Investigateur principal